The influence of sparse data sampling on population pharmacokinetics: A post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 668-676

  Ariano, Robert E ^a,b,c   Duke, Peter C ^b   Sitar, Daniel S ^b,c  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Morphine; Population pharmacokinetics; Sparse sampling

Indexed keywords

MORPHINE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; ELECTIVE SURGERY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; POST HOC ANALYSIS; VALIDATION PROCESS;

ADULT; ANALGESICS, OPIOID; COMPUTER SIMULATION; DRUG MONITORING; HUMANS; MALE; MODELS, BIOLOGICAL; MORPHINE; PREDICTIVE VALUE OF TESTS; SAMPLING STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84858606866     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.023     Document Type: Article

References (17)

1. Bréant V., Charpiat B., Sab J.M., et al. How many patients and blood levels are necessary for population pharmacokinetic analysis?. Eur J Clin Pharmacol 1996, 51:283-288.
2. Lee H.S., Khoo Y.M., Chirino-Barcelo Y., et al. Caffeine in apnoeic Asian neonates: a sparse data analysis. Br J Clin Pharmacol 2002, 54:31-37.
3. Ariano R.E., Zelenitsky S.A., Nyhlen A., Sitar D.S. An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics. J Clin Pharmacol 2005, 45:832-835.
4. Sitar D.S., Duke P.C., Owen J.A., et al. Kinetic disposition of morphine in young males after intravenous loading and maintenance infusions. Can Anaesth Soc J 1986, 33:145-149.
5. Owen J.A., Sitar D.S., Berger L., et al. Age-related morphine kinetics. Clin Pharmacol Ther 1983, 34:364-367.
6. Jelliffe R.W., Schumitzky A., Van Guilder M. User Manual for Version 11.0 USC*PACK Collection of PC Programs 2002, Laboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, Calif.
7. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974, 19:716-723.
8. Sheiner L.B., Beal S.L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981, 9:503-512.
9. Boerner U. The metabolism of morphine and heroin in man. Drug Metab Rev 1975, 4:39-73.
10. Lotsch J., Stockmann A., Kobal G., et al. Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther 1996, 60:316-325.
11. Samara E., Granneman R. Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Clin Pharmacokinet 1997, 32:294-312.
12. Vermeulen A., Piotrovsky V., Ludwig E.A. Population pharmacokinetics of risperidone and 9-hydroyrisperidone in patients with acute episodes associated with bipolar I disorder. Pharmacokinet Pharmacodyn 2007, 34:183-206.
13. de Hoog M., Schoemaker R.C., van den Anker J.N., Vinks A.A. NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates. Ther Drug Monit 2002, 24;:359-365.
14. Bustad A., Terziivanov D., Leary R., et al. Parametric and nonparametric population methods. Their comparative performance in analyzing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006, 45:365-383.
15. D'Argenio D.Z. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981, 9:739-756.
16. Hooker A.C., Foracchia M., Dodds M.G., Vicini P. An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann Biomed Eng 2003, 31:98-111.
17. Vermes A., MathÔt R.A., van der Sijs I.H., et al. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM. Ther Drug Monit 2000, 22:676-687.